Welcome to our dedicated page for OPHD news (Ticker: OPHD), a resource for investors and traders seeking the latest updates and insights on OPHD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OPHD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OPHD's position in the market.
Opus Holdings (OTC: CATV), soon to be renamed to OTC: OPHD, has announced key leadership appointments to transform into a premier business incubator. Following CEO Susan Ward's appointment, the company added Israel Mirsky as Senior Advisor and Natacha St. Louis for Business Development, bringing over 65 years of combined experience.
The company reported significant achievements including $500K in Q4 revenue, elimination of $830K in debt, and reduction of over 8 billion dilutive shares. Q1 2025 sales have maintained stability. The new leadership team aims to execute 3-5 spin-offs within 24 months across biotech, wellness, tech, and consumer goods sectors.
Mirsky brings experience from OMD Worldwide and Intel, while St. Louis contributes 20 years in economic development and compliance. The company's incubation strategy focuses on acquiring, developing, and transitioning private companies into public markets.
